DEGREE OF METABOLIC DYSFUNCTION IS LINKED TO STEATOHEPATITIS (MASH), FIBROSIS, AND HIGHER CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

被引：0
|
作者：
Kim, David [1 ]
Abboud, Yazan [1 ]
Ismail, Mohamed [1 ]
Goyal, Ritik Mahaveer [1 ]
Pyrsopoulos, Nikolaos [1 ]
Kim, Hyunseok [2 ]
Hajifathalian, Kaveh [1 ]
Al-Khazraji, Ahmed [1 ]
机构：
[1] Rutgers New Jersey Med Sch, Newark, NJ USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
602
引用
收藏
页码：S441 / S442
页数：2
相关论文
共 50 条
  • [31] Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis
    Saito, Takashi
    Tsuchishima, Mutsumi
    Tsutsumi, Mikihiro
    George, Joseph
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (12)
  • [32] YAssociation between severity of liver and cardiovascular damage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) according to cardiovascular risk categories
    Curra, J.
    Cespiati, A.
    Pulixi, E. A.
    Lombardi, R.
    Oberti, G.
    Bertelli, C.
    Fatta, E.
    Pisano, G.
    Santomenna, F.
    Smith, D.
    Cinque, F.
    Fracanzani, A. L.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S52 - S52
  • [33] Cardiovascular Disease Risk Is Increased In Adolescents With Metabolic Dysfunction-associated Steatotic Liver Disease
    Short, Kevin R.
    Palle, Sirish K.
    Tryggestad, Jeanie B.
    Hellman, Diana A.
    Sciarrillo, Christina M.
    Emerson, Sam R.
    Friedman, Jacob E.
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (10) : 680 - 680
  • [34] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause?
    Chen, R.
    Salamone, A.
    Abbati, C.
    Capelli, R.
    Santangeli, E.
    Stefanini, B.
    Indre, M. G.
    Ravaioli, F.
    Piscaglia, F.
    Ferri, S.
    DIGESTIVE AND LIVER DISEASE, 2025, 57
  • [35] The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease
    Platek, Anna E.
    Szymanska, Julia A.
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2024, 19 (03): : 290 - 295
  • [36] ENHANCING TRADITIONAL FIBROSIS PREDICTION MODELS WITH MACHINE LEARNING IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Kim, David
    Qureshi, Imran
    Ismail, Mohamed
    Abboud, Yazan
    Pyrsopoulos, Nikolaos
    Kim, Hyunseok
    Hajifathalian, Kaveh
    Al-Khazraji, Ahmed
    HEPATOLOGY, 2024, 80 : S587 - S588
  • [37] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
    Loomba, Rohit
    Hartman, Mark L.
    Lawitz, Eric J.
    Vuppalanchi, Raj
    Boursier, Jerome
    Bugianesi, Elisabetta
    Yoneda, Masato
    Behling, Cynthia
    Cummings, Oscar W.
    Tang, Yuanyuan
    Brouwers, Bram
    Robins, Deborah A.
    Nikooie, Amir
    Bunck, Mathijs C.
    Haupt, Axel
    Sanyal, Arun J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 299 - 310
  • [38] Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)
    Wang, Shuang
    Friedman, Scott L.
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (716)
  • [39] Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Ramanathan, Raghu
    Patwa, Sohum A.
    Ali, Ahmad Hassan
    Ibdah, Jamal A.
    CELLS, 2023, 12 (24)
  • [40] PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND SEVERE FIBROSIS HAVE WORSE EXECUTIVE FUNCTION PERFORMANCE
    Weinstein, Ali
    de Avila, Leyla
    Lam, Brian
    Stepanova, Maria
    Price, Jillian
    Escheik, Carey
    Gerber, Lynn
    Younossi, Zobair
    HEPATOLOGY, 2024, 80 : S827 - S828
12345